Figure 2From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)Kaplan-Meier curves according to first-line treatment (oxaliplatin-based regimen) with/without bevacizumab. (A) Progresion-free survival (PFS), (B) Overall survival (OS).Back to article page